• Farah N. K. Bhatti
  • John Wallwork
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 225)


While transplantation is an established form of treatment for many end stage disease processes that lead to heart failure, the number of transplants performed is limited by a relative lack of donor organs. This has led not only to a levelling off in heart transplant activity world-wide, but actually to a decrease in the number of operations performed in 1995 and 1996, despite the use of older organ donors each year. Although waiting lists are kept artificially low by patient selection, the disparity between growing waiting lists and falling transplant numbers continues to widen leading to a proportion of people dying whilst awaiting transplant. In the United Kingdom in 1996, of people waiting for a heart, only 63% were transplanted, and 14% died while waiting.1 Figures from the United Network for Organ Sharing (UNOS) at the end of 1996 show a similar situation, with 3700 people waiting for a heart transplant in the U.S.A., 2343 transplants being performed, and 744 deaths on the waiting list. The mismatch between the waiting lists and transplants actually performed is depicted, for all organs, in Figure 1.2


Total Artificial Heart Membrane Cofactor Protein Decay Accelerate Factor Hyperacute Rejection Acute Vascular Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 3.
    Cooper DKC and Ye Y. Experience with Clinical Heart Xenotransplantation. In: Xenotransplantation, The Transplantation of Organs and Tissues Between Species. Eds. Cooper DKC, Kemp E., Reemtsma, White DJG. Springer-Verlag; 1991:541/557.Google Scholar
  2. 4.
    Cooper DKC, Ye Y, Rolf JLL, Zuhdi N. The pig as a potential donor for manIn: Xenotransplantation, The Transplantation of Organs and Tissues Between Species. Eds. Cooper DKC, Kemp E., Reemtsma, White DJG. Springer-Verlag; 1991:481–500.Google Scholar
  3. 5.
    Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970;2(4):550–6.PubMedGoogle Scholar
  4. 6.
    Cooper DKC, Human PA, Lexer G et al. Effects of Cyclosporine and Antibody Adsorption on pig cardiac xenograft survival. J Heart Transplant 1988; 7: 238–46.PubMedGoogle Scholar
  5. 7.
    Sandrin MS, Fodor WL, Cohney S et al. Reduction of the major porcine xenoantigen Gal α(1,3) Gal by the expression of α(1,2) fucosyltransferase. Xenotransplantation 1996; 3: 134–40CrossRefGoogle Scholar
  6. 8.
    Atkinson JP, Oglesby TJ, White D, Adams EA, Liszewski MK. Separation of self from non-self in the complement: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86(1):27–30.PubMedGoogle Scholar
  7. 9.
    Oglesby TJ, White D, Tedja I et al. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay accelerating factor. Transactions of the Associations of American Physicians CIV. 1991; 164–72.Google Scholar
  8. 10.
    Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1(9): 964–6PubMedCrossRefGoogle Scholar
  9. 11.
    Langford GA, Yannoutsos E, Cozzi E et al. Production of pigs transgenic for human decay accelerating factor. Trans Proc 1994; 26(3): 1400–1.Google Scholar
  10. 12.
    Schmoeckel M, Nollert G, Shahmohammadi M et al. Transgenic human decay accelerating factor makes normal pigs function as a concordant species. Heart Lung Transplant 1997 Jul;16(7):758–64.Google Scholar
  11. 13.
    Hasan RI, et al. Prolonged survival of hamster to rat heart xenografts with cyclophosphamide therapy Transplant Proc 1992 Apr; 24(2): 517–8.PubMedGoogle Scholar
  12. 14.
    Waterworth PD, Cozzi E, Tolan MJ et al. Pig to primate cardiac xenotransplantation and cyclophosphamide therapy. Trans Proc 1997;29:899–900.CrossRefGoogle Scholar
  13. 15.
    Stark JH, Smit JA, Gridelli B. Sensitivity of baboon lymphocytes to cyclosporin A and FK506: relative resistance of alloactivated cells to CyA Transplant Int 1994; 7: 372–8.CrossRefGoogle Scholar
  14. 16.
    Schmoeckel M, Bhatti FNK, Zaidi A et al. Orthotopic heart transplantation in a transgenic pig to primate model Transplantation 1998;65(12): 1570–7.PubMedCrossRefGoogle Scholar
  15. 17.
    Morris RE. Mechanisms of action of new immunosuppressive drugs. Therapeutic Drug Monitoring 1995; 17(6):564–9.PubMedCrossRefGoogle Scholar
  16. 18.
    Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nature Med. 1997 Mar; 3(3): 282–6.PubMedCrossRefGoogle Scholar
  17. 19.
    Smith JA, Boyd KM, Eds. Lives in the Balance. The Ethics of using animals in biomedical research. The Report of a Working Party of the Institute of Medical Ethics. OUP 1991.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Farah N. K. Bhatti
  • John Wallwork

There are no affiliations available

Personalised recommendations